Highlights

  • Ansell reported FY26 full-year results in August 2026.
  • The group supplies protective equipment across healthcare and industrial settings.
  • Its H1 FY26 sales were $1,026.6 million in company presentations.
  • Foreign exchange movements affected reported sales and EBIT in H1 FY26.

Ansell Limited (ASX:ANN) supplies protective solutions for healthcare, industrial and specialist workplace applications across international markets. The company released its FY26 full-year results in August 2026, following its February half-year reporting. In its H1 FY26 presentation, Ansell reported sales of $1,026.6 million. These disclosures provide an operating context shaped by demand for gloves and other protection products, manufacturing and distribution expenses, and the effects of reporting sales across several currencies.

Interpreting the Half-Year Sales Figure

Ansell Limited (ASX:ANN) recorded H1 FY26 sales of $1,026.6 million in its financial presentation. Sales reflect the income earned through the company’s protective products business, not the amount retained as profit after manufacturing, logistics and corporate expenses. Product categories are exposed to different purchasing schedules and end markets. Healthcare customers may have recurring requirements associated with clinical procedures, while industrial users purchase equipment in connection with workplace tasks and safety standards. A combined sales figure does not identify the change in every product category. Understanding the company’s results therefore requires attention to the relevant business segments as presented in its reporting.

Currency Effects in FY26

Ansell Limited (ASX:ANN) identified foreign exchange movements as a factor in its H1 FY26 results. Its half-year results material recorded a $21.1 million benefit to sales from exchange-rate movements compared with H1 FY25, while total foreign exchange effects on EBIT were a negative $1.6 million after hedge contract movements. This demonstrates why currency translation and hedging should be considered separately. A favourable reported sales translation effect need not produce an equivalent earnings benefit, particularly when hedges or costs move differently. Ansell’s international manufacturing and sales footprint makes the precise reporting basis important when comparing periods.

Operating Areas and Customer Requirements

Ansell Limited (ASX:ANN) provides hand and body protection products used in healthcare facilities, laboratories, manufacturing and other workplaces. These products fulfil differing protective and operational purposes, so demand cannot be reduced to one general market condition. The company’s operating structure involves manufacturing capabilities, commercial relationships and supply arrangements across multiple locations. Costs and product mix can affect profitability even if total sales remain relatively stable. In this setting, company financial releases help distinguish changes driven by customer purchasing from those driven by foreign exchange rates or costs. Such distinctions are important when considering a multinational protective equipment supplier.

Results Calendar and Information Context

Ansell Limited (ASX:ANN) published FY26 half-year results in February and full-year results in August 2026. Its financial calendar recorded a final dividend payment date of 17 September 2026 and an annual general meeting scheduled for November 2026. Those dates form part of the company’s 2026 reporting and corporate calendar, although they are separate from the day’s quoted share price. The timing of a financial release identifies the period being reported and should not be confused with the date of a market observation. Likewise, a financial calendar entry provides an event date but not a basis for predicting subsequent business performance.

Key Insights

Ansell Limited (ASX:ANN) reported H1 FY26 sales of $1,026.6 million and subsequently published its FY26 annual results. Its reporting highlights the relevance of international currency movements to sales and earnings, in addition to the company’s healthcare and industrial product activities. The $45.39 share price on 30 October 2026 is a dated trading figure rather than a substitute for its reported operating and financial measures.